Vol. 15 Nbr. 1, March 2010
- SILCAAT and ESPRIT: taking stock.
- HIV immunology: what lessons can we learn from recent vaccine trials?
- Lymphocyte activation in HIV-1 infection: time for quality control.
- A review of the use of activation markers in Africa.
- Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.